Cabaletta Bio’s Post

PharmaVoice breaks down the potentially seismic impacts of CRISPR-based therapies, with data from Norstella companies Citeline and Evaluate Ltd and commentary from Jen (Goldenberg) Klarer of The Dedham Group, where Jen underscores the promise and complexity of these treatments. Read the article here: https://ow.ly/pybG50QjgaM. #Pipeline2Patient #Norstella

📣 We are thrilled to announce the launch of our new Cilia Beat Frequency analysis assay for lung small airway epithelium cells (SAEC). This cutting-edge software enables researchers to assess the effect of drugs and chemicals on the function of cilia. The new, functionally-validated assay generates reliable and predictive in vitro data on the activity of the beating cilia of the airways. It allows the assessment of dosing on mucus clearance, the function of cilia, and evaluation of drug efficacy in reversing disease-like conditions. Unlock a comprehensive, high-sensitivity set of data that accurately measures the effect of your compound, including fast-acting ones, on mucociliary clearance. Dr Dr Mike Nicholds, CEO and Co-Founder, Newcells Biotech, commented: “CiliaBeat complements our existing capabilities, giving customers more options to gain physiologically-relevant insights into this crucial organ type.” Amy Mawdesley, Account Manager, is on hand at the European Respiratory Society in Vienna to answer your questions about CiliaBeat! Find out more here: https://lnkd.in/extRdN2R #Newcells #LungAssay #Cilia #SAEC

We are thrilled to be presenting data on the clinical progress with our masked anti-CTLA-4 ADG126 plus pembrolizumab at this year’s ESMO! Tune in for the latest results with this IO doublet in 3L MSS CRC, including data at the 10 mg/kg Q3W dose in a larger patient cohort! The poster will report results of an ongoing phase 1b/2 trial of Adagene’s masked anti-CTLA-4 SAFEbody in combination with the anti-PD-1 treatment pembrolizumab. The title is: Increased Therapeutic Index of Muzastotug (Muza, ADG126), a Masked Anti-CTLA-4 SAFEbody®, in Combination with Pembrolizumab (Pembro) Enables Significant Clinical Benefits and Supports Further Clinical Development in Patients with Metastatic MSS CRC #Adagene #innovation #treatment #clinicalprogress https://loom.ly/KHCaYp8

Thank you to all of the providers who support us and trust BENEV Exosomes with their patients! A special shoutout to… 💧Mari De La Roca, LME (@pinskiderm) …for sharing what her experience has been like while using BENEV Exosomes! *Statements made by each provider are of their own experience and not the statements of BENEV Company Inc. #benevskinscience #benevexosomes #exosomes #exosomeregenerativecomplex #exocobio #benev+exocobio #exosometechnology *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.

Join us today at 4 PM in the Innovation Zone at Phacilitate Advanced Therapies Week 2024 (#ATW2024). We'll be discussing 'Revolutionizing Regenerative Medicine: #BonoFill and #MesenCure - Pioneering Accessible and Economical Advanced Therapies at Bonus Biogroup.' Don't miss this insightful session on groundbreaking advancements in cell therapy and tissue engineering!

Did you know metabolic dysfunction-associated steatohepatitis (MASH) is caused by an excess of fat cells in the liver? Our drug candidate for MASH, entering Phase 2a clinical trials this year, has the potential to be best-in-class based on recent data we presented. Learn more here: https://brnw.ch/21wHuxk

🚀 Unleash the Power of B Cell Expansion with B-Xpander™! 🚀 Are you looking to revolutionize your B cell expansion protocols for clinical research and immunotherapies? Look no further than B-Xpander™ by AdipoGen Life Sciences. Why B-Xpander™? ✨ Enhanced Activation and Proliferation 🧬 High Bioactivity and Purity 📊 Consistency and Safety Read more via the link in the comments 🔗 #Immunotherapy #BCellExpansion #ClinicalResearch #AdipoGenLifeSciences #BXpander #Biotech

Thank you to all of the providers who support us and trust BENEV Exosomes with their patients! A special shoutout to… 💧William Gael, MD, FACP, FACEP (@docmanhattannyc) …for sharing what his experience has been like while using BENEV Exosomes! *Statements made by each provider are of their own experience and not the statements of BENEV Company Inc. #benevskinscience #benevexosomes #exosomes #exosomeregenerativecomplex #exocobio #benev+exocobio #exosometechnology *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.

Introducing the Coyote Bioscience FlashDetect™ Flash10, a fully automated rapid PCR system that brings unmatched precision and efficiency to molecular diagnostics. Designed to operate seamlessly with Coyote's LyocartD and LyocartE cartridges, it ensures a contamination-free process from sample loading through to qPCR.    The Flash10 system not only provides results in under 25 minutes but also allows for the independent operation of four samples simultaneously, enhancing throughput and efficiency. Known for its high sensitivity across a broad range of tests, the system's intuitive design facilitates easy operation. It grants access to a diverse test menu, including SARS-CoV-2 & FluA/B & RSV, MRSA, HSV-1&2, MG&TV&MH, and more.   A life changing tool for clinical settings, the Flash10 redefines the standards of near-patient testing.    #PCR #PointofCare #Healthcare #MedicalEquipment #MolecularDiagnostics #Biorus

Yes, access is an issue for Sotyktu, but it's not the only one.... According to Spherix Global Insights' latest data, safety perceptions are shifting for Bristol Myers Squibb's Sotyktu. Compared to last year, a growing percentage of dermatologists agree they are hesitant to prescribe Sotyktu despite the "clean" label. These perceptions are now impacting the TYK2 class as fewer physicians report that the TYK2 mechanism fills an unmet need in plaque psoriasis. Although this will likely impact TYK2s in development, this could bode well for other orals in the pipeline for plaque psoriasis. Read more here: https://lnkd.in/eNsd8SCu #Sotyktu #BMS #psoriasis